TABLE 3.

Characteristics of patients in whom clinical failure occurred

Treatment group	Age (yr)	Sexa	Type of infection	Pathogen	Susceptibilityb	Treatment duration (days)	APACHE II score	Sepsis syndrome	Follow-up
Meropenem	82	F	Sepsis syndrome	None		5	13	Yes	Changed to cefuroxime and gentamicin
	69	M	Intra-abdominal	Escherichia coli, Streptococcus oralis	S	3	18	Yes	Died after ruptured infected aorta bypass
	74	F	Pneumonia	None	ND	8	12	No	No subsequent antibiotics
	78	F	Intra-abdominal	Klebsiella oxytoca, Escherichia coli, Bacteroides spp., Staphylococcus epidermidis	S	4	14	No	Changed to piperacillin-tazobactam
	74	M	Sepsis syndrome	Staphylococcus aureus	S	8	20	Yes	Changed to meropenem and vancomycin
	69	M	Pneumonia	None	NA	6	10	No	No subsequent antibiotics
	83	M	Pneumonia	Streptococcus pneumoniae	S	0	16	No	No subsequent antibiotics
Cefuroxime-gentamicin (±metronidazole)	68	M	Intra-abdominal	Klebsiella pneumonia	S	17	19	No	Changed to cotrimoxazole
			Pneumonia	Pseudomonas aeruginosa	R
	78	M	Sepsis syndrome	Enterococcus spp.	R	3	21	Yes	No subsequent antibiotics
	77	M	Sepsis syndrome	Serratia spp.	I	3	22	Yes	Changed to cotrimoxazole
			Pneumonia	Haemophilus influenzae	S
	76	F	Pneumonia	Escherichia coli	S	6	25	No	No subsequent antibiotics
				Streptococcus haemolyticus	ND				Died after asystole
	71	M	Pneumonia	None	NA	4	14	No	Changed to erythromycin
	73	M	Pneumonia	Enterobacter spp.	I	3	23	No	Changed to imipenem-cilastatin
	83	M	Pneumonia	Enterobacter cloacae	S	7	19	No	Changed to piperacillin, tobramycin, and later to ceftazidime
				Pseudomonas aeruginosa	R

^aF, female. 

^bS, susceptible; ND, no data available; NA, not applicable; R, resistant; I, intermediate.